Succinyltransferase inhibitors (CPT1A inhibitors) developed for this pathway can be combined with surgery to block ECM remodeling and reduce the risk of tumor cells shedding and metastasis during surgery[138,193,194]. Here, CPT1A is linked to neoplasm.